| Date | Time | Source | Announcement |
|---|---|---|---|
| 16 May 2005 | 07:00 AM | Phase II trials of TroVax | |
| 12 May 2005 | 04:00 PM | Holding(s) in Company | |
| 12 May 2005 | 10:24 AM | 2005 ASCO Annual Meeting | |
| 10 May 2005 | 12:05 PM | AGM Statement | |
| 09 May 2005 | 07:00 AM | European Patent Granted | |
| 05 May 2005 | 07:00 AM | Preclinical Effiancy Data | |
| 27 Apr 2005 | 04:00 PM | Holding(s) in Company | |
| 22 Apr 2005 | 03:03 PM | Holding(s) in Company | |
| 20 Apr 2005 | 04:41 PM | Holding(s) in Company | |
| 15 Apr 2005 | 03:49 PM | Holding(s) in Company | |
| 29 Mar 2005 | 07:00 AM | Notice of AGM | |
| 29 Mar 2005 | 07:00 AM | Notice of Allowance | |
| 22 Mar 2005 | 11:42 AM | Director Shareholding | |
| 21 Mar 2005 | 07:00 AM | Final Results | |
| 14 Mar 2005 | 12:47 PM | LentiVector Technology | |
| 10 Mar 2005 | 07:00 AM | Presenting at SG Cowen Conf | |
| 04 Mar 2005 | 09:25 AM | Directorate Change | |
| 04 Mar 2005 | 07:00 AM | Notice of Results | |
| 02 Mar 2005 | 07:00 AM | Results from 3 Phase II Trial | |
| 01 Mar 2005 | 12:17 PM | Holding(s) in Company | |
| 17 Feb 2005 | 01:54 PM | Progress Report | |
| 07 Feb 2005 | 07:00 AM | Offer Talks Terminated | |
| 01 Feb 2005 | 07:00 AM | Licensing Agreement | |
| 31 Jan 2005 | 09:18 AM | Holding(s) in Company | |
| 28 Jan 2005 | 07:00 AM | Rule 2.10 Announcement | |
| 27 Jan 2005 | 07:00 AM | Rule 2.10 Announcement | |
| 26 Jan 2005 | 05:39 PM | Holding(s) in Company | |
| 21 Jan 2005 | 11:26 AM | Holding(s) in Company | |
| 21 Jan 2005 | 07:00 AM | Rule 2.10 Announcement | |
| 20 Jan 2005 | 07:00 AM | Rule 2.10 Announcement | |
| 19 Jan 2005 | 07:00 AM | Stmnt re Share Price Movement | |
| 12 Jan 2005 | 07:00 AM | Holding(s) in Company | |
| 05 Jan 2005 | 07:00 AM | Agreement with Biogen Idec | |
| 16 Dec 2004 | 07:00 AM | New Preclinical Data | |
| 13 Dec 2004 | 07:00 AM | Licence Agreement | |
| 19 Nov 2004 | 02:15 PM | Blocklisting Interim Review | |
| 01 Nov 2004 | 04:00 PM | Holding(s) in Company | |
| 29 Oct 2004 | 07:00 AM | Extended Collaboration | |
| 12 Oct 2004 | 10:37 AM | Director Shareholding | |
| 01 Oct 2004 | 06:06 PM | Holding(s) in Company | |
| 22 Sep 2004 | 04:00 PM | Holding(s) in Company | |
| 17 Sep 2004 | 04:06 PM | Holding(s) in Company | |
| 17 Sep 2004 | 07:00 AM | License Agreement | |
| 02 Sep 2004 | 04:30 PM | Holding(s) in Company | |
| 01 Sep 2004 | 07:01 AM | TroVax Phase II Trials | |
| 01 Sep 2004 | 07:00 AM | Interim Results | |
| 24 Aug 2004 | 09:24 AM | Notice of WebCast | |
| 18 Aug 2004 | 07:00 AM | Appointment of Broker | |
| 15 Jul 2004 | 04:30 PM | Holding(s) in Company | |
| 06 Jul 2004 | 04:30 PM | Holding(s) in Company |
Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.
Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.